Autoimmune Lymphoproliferative Syndrome Type III: An Indefinite Disorder

References

• Fisher G., Rosenberg F., Straus S., Dale J., Middleton L., Lin A., Strober W., Lenardo M., Puck J. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935–946
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F., Deist F. L., Hivroz C., Roberts I., Debatin K. M., Fisher A., Villartay J. -P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347–1349
   PubMed Web of Science ®Google Scholar
• Drappa J., Vaishnaw A. K., Sullivan K. E., Chu J. -L., Elkon K. B. Fas gene mutation in the Canale-Smith syndrome, an inherited lymphoproliferative Disorder associated with autoimmunity. New England Journal of Medicine 1996; 335: 1643–1649
   PubMed Web of Science ®Google Scholar
• Bettinardi A., Brugnoni D., Quiros-Roldan E., Malagoli A., Grutta S. L., Correra A., Notarangelo L. D. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 1997; 89: 902–909
   PubMed Web of Science ®Google Scholar
• Pensati L., Costanzo A., Ianni A., Accapezzato D., Iorio R., Natoli G., Nisini R., Almerighi C., Balsano C., Vajro P., Vegnente A., Levrero M. Fas/Apol mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997; 113: 1384–1389
   PubMed Web of Science ®Google Scholar
• Sneller M. C., Wang J., Dale J. K., Strober W., Middelton L. A., Choi Y., Flaisher T. A., Lim M. S., Jaffe E. S., Lenardo J. J., Straus S. E. Clinical, immunologic and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997; 89: 1341–1348
   PubMed Web of Science ®Google Scholar
• Kasahara Y., Wada T., Niida Y., Yachie A., Seki H., Ishida Y., Sakai T., Koizumi F., Koizumi S., Miyawaki T., Taniguchi N. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. International Immunology 1998; 10: 195–202
   PubMed Web of Science ®Google Scholar
• Infante A. J., Britton H. A., DeNapoli T., Middelton L. A., Lenardo M. J., Jackson C. E., Wang J., Fleisher T., Straus S. E., Puck J. M. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs apoptosis. 1998 1998; 133: 629–633
   Google Scholar
• Canale V. C., Smith C. H. Chronic lymphadenopathy simulating malignant lymphoma. Journal of Pediatrics 1967; 70: 891–899
   PubMed Web of Science ®Google Scholar
• Sneller M. C., Straus S. E., Jaffe E. S., Jaffe J. S., Fleisher T. A., Stetler-Stevenson M., Strober W. A novel lymphoproliferative/autoimmune syndrome resembling murine Ipr/gld disease. Journal of Clinical. Investigation 1992; 90: 334–341
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R., Brannan C., Copeland N., Jenkins N., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317
   PubMed Web of Science ®Google Scholar
• Takahashi T., Tanaka M., Brannan C., Jenkins N., Copeland N., Suda T., Nagata S. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994; 76: 969–976
   PubMed Web of Science ®Google Scholar
• van der Werff ten Bosch J., Demanet C., Balduck N., Bakkus M., De Raeve H., Desprechins B., Otten J., Thielemans K. The use of the anti malaria drug Fansidar (pyrimethamine and sulfadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency. British Journal of Haematology 1998; 102: 578–581
   PubMed Web of Science ®Google Scholar
• Sleight B., Prasad V., DeLaat C., Steele P., Ballard E., Arceci R., Sidman C. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow transplantation 1998; 22: 375–380
   PubMed Web of Science ®Google Scholar
• Vaishnaw A. K., Orlinck J. R., Chu J. -L., Krammer P. H., Chao M. V., Elkon K. B. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. Journal of Clinical Investigation 1999; 103: 355–363
   PubMed Web of Science ®Google Scholar
• Jackson C. E., Fischer R. E., Hsu A. P., Anderson S. M., Choi Y., Wang J., Dale J. K., Fleisher T. A., Middelton L. A., Sneller M. C., Lenardo M. J., Straus S. E., Puck J. M. Autoimmune lymphoproliferative syndrome with defective fas genotype influence penetrance. American Journal of Human Genetics 1999; 64: 1002–1014
   PubMed Web of Science ®Google Scholar
• Peters A., Kohfink B., Martin H., Griesinger F., Wormann B., Gahr M., Roesler J. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Experimental Hematology 1999; 27: 868–874
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F., Blachère S., Danielan S., De Villartay J., Oleastro M., Solary E., Bader-Meunier B., Arkwright P., Pondaré C., Bernaudin F., Chapel H., Nielsen S., Berrah M., Fischer A., Le Deist F. Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant interfering expression of the clinical phenotype. Blood 1999; 94: 2575–2582
   PubMed Web of Science ®Google Scholar
• Aspinall A., Pinto A., Auer L., Bridges P., Luider J., Dimnik L., Patel K., Jorgenson K., Woodman R. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia. Blood Cells Molecular Discourse 1999; 25: 227–238
   PubMed Web of Science ®Google Scholar
• van der Burg M., de Groot R., Comans-Bitter W., den Hollander J., Hooijkaas H., Neijens H., Berger R., Oranje A., Langerak A., van Dongen J. Autoimmune Lymphoproliferative Syndrome (ALPS) in a child from cosanguineous parents: a dominant or recessive disease?. Pediatric Research 2000; 47: 336–343
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B., Rieux-Laucat F., Croisille L., Yvart J., Mielot F., Dommergues J., Ledeist F., Tchernia G. Dyserythropoiesis associated with a Fas-deficient condition in childhood. British Journal of Haematology 2000; 108: 300–304
   PubMed Web of Science ®Google Scholar
• Shenoy S., Arnold S., Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. Journal of Pediatrics 2000; 136: 682–687
   PubMed Web of Science ®Google Scholar
• Wu J., Wilson J., He J., Xiang L., Schur P., Mountz J. Fas Ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. Journal of Clinical Investigation 1996; 98: 1107–1113
   PubMed Web of Science ®Google Scholar
• Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M. Apoptosis signaling by death receptors. European Journal of Biocheimstry 1998; 254: 439–459
   PubMedGoogle Scholar
• Itoh N., Nagata S. A novel protein domain required for apoptosis-Mutational analysis of human fas antigen. Journal of Biological Chemistry 1993; 268: 10932–10937
   PubMed Web of Science ®Google Scholar
• Kischkel F., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P., Peter M. Cytotoxicity-dependent APO-1 (FAS/CD95) associated proteins form a death-inducing signal complex (DISC) with the receptor. Embo Journal 1995; 4: 5579–5588
   Google Scholar
• Boldin M., Varfolomeev E., Pancer Z., Mett I., Camonis J., Wallach D. A novel protein that interacts with the death domain of Fas/APO-1 contains a sequence motif related to the death domain. Journal of Biological Chemistry 1995; 270: 7795–7798
   PubMed Web of Science ®Google Scholar
• Chinnaiyan A., O'Rourke K., Tewari M., Dixit V. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505–512
   PubMed Web of Science ®Google Scholar
• Boldin P., Goncharov T., Goltsev Y., Wallach D. Involvement of MACH, a novel MORTI/FADD-interacting protease, in Fas/APO-1 and TNF receptor induced cell death. Cell 1996; 85: 803–815
   PubMed Web of Science ®Google Scholar
• Fernandez-Alnemri T., Armstrong R., Krebs J., Srinivasula S., Wang L. In vitro activation of CPP32 and McH3 by McH4, a novel human apoptotic cysteine protease containing 2 FADD-like domains. Proceedings of the National Academy of Science of the USA 1996; 93: 7464–7469
   PubMed Web of Science ®Google Scholar
• Muzio M., Chinnaiyan A., Kischkel F. K. O. R., Shevchenko A., Ni J., Scaffidi C., Bretz J., Zhang M., Gentz R., Mann M., Krammer P., Peter M., Dixit V. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex;. Cell 1996; 85: 817–827
   PubMed Web of Science ®Google Scholar
• Medema J., Scaffidi C., Kischkel F., Shevchenko A., Mann M., Krammer P., Peter M. Fice is activated by association with the CD95 death inducing signal complex (DISC). EMBO Journal 1997; 16: 2794–2804
   PubMed Web of Science ®Google Scholar
• Hasegawa J., Kamada S., Kamiike W., Shimizu S., Imazu T., Matsuda H., Tsujimoto Y. Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis. Cancer Research 1996; 56: 1713–1718
   PubMed Web of Science ®Google Scholar
• Schlegel J., Peters I., Orrenius S., Miller D., Thornberry N., Yamin T., Nicholson D. CPP32/apopain is a key Interleukin 1-beta converting enzyme-like protease involved in Fas-mediated apoptosis. Journal of Biological Chemistry 1996; 271: 1841–1844
   PubMed Web of Science ®Google Scholar
• Enari M., Hug H., Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375: 78–81
   PubMed Web of Science ®Google Scholar
• Stennicke H., Jurgensmeier J., Shin H., Deveraux Q., Wolf B., Yang X., Zhou Q., Ellerby H., Ellerby L., Bredesen D., Green D., Reed J., Froelich C., Salvesen G. Pro-caspase-3 is a major physiologic target of caspase-8. Journal of Bioogical Chemistry 1998; 273: 27084–27090
   PubMed Web of Science ®Google Scholar
• Zheng T., Schlosser S., Dao T., Hingorani R., Crispe I., Boyer J., Flavell R. Caspase-3 controls both cytoplasmatic and nuclear events associated with fas-mediated apoptosis in vivo. Proceedings of the National Academy of Science of the USA 1998; 95: 13618–13623
   PubMed Web of Science ®Google Scholar
• Jackson P., Puck J. Autoimmune Lymphoproliferative Syndrome, a disorder of apoptosis. Current Opinion in Pediatrics 1999; 11: 521–527
   PubMedGoogle Scholar
• Martin D. A., Zheng I., Siegel R. M., Huang B., Fisher G. H., Wang J., Jackson C. E., Puck J. M., Dale J., Straus S. E., Peter M. E., Krammer P. H., Fesik S., Lenardo M. J. Defective CD95/Apo-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proceedings of the National Academy of Science of the USA 1999; 96: 4552–4557
   PubMed Web of Science ®Google Scholar
• Lim M. S., Straus S. E., Dale J. K., Fleisher T. A., Stetler-Stevenson M., Strober W., Sneller M. C., Puck J. M., Lenardo M. J., Elenitoba-Johnson K., Lin A. Y., Raffield M., Jaffe E. S. Pathological findings in human autoimmune lymphoproliferative syndrome. American Journal of Pathology 1998; 153: 1541–1550
   PubMed Web of Science ®Google Scholar
• Dianzani U., Bragardo M., DiFranco D., Alliaudi C., Scagni P., Buonfiglio D., Redoglia V., Bonissoni S., Correra A., Dianzani I., Ramenghi U. Deficiency of Fas apoptosis pathway without fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood 1997; 89: 2871–2879
   PubMed Web of Science ®Google Scholar
• van der Werff ten Bosch J., Delabie J., Böhler T., Verschuere J., Thielemans K. Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. British Journal of Haematology 1999; 106: 1045–1048
   PubMed Web of Science ®Google Scholar
• Strobel P., Nanan R., Gattenlohner S., Muller-Deubert S., Muller-Hermelink H. K., Kreth H. W., Marx A. Reversible monoclonal lymphadenopathy in autoimmune lymphoproliferative syndrome with functional FAS (CD95/APO-1) deficiency. American Journal of Surgical Pathology 1999; 23: 829–837
   PubMed Web of Science ®Google Scholar
• Ramenghi U., Bonissoni S., Migliaretti G., DeFranco S., Bottarel F., Gambaruto C., DiFranco D., Priori R., Conti F., Dianzani I., Valesini G., Merletti F., Dianzani U. Deficiency of the fas apoptosis pathway without fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood 2000; 95: 3176–3182
   PubMed Web of Science ®Google Scholar
• Tepper C. G., Jayadev S., Liu B., Bielawska A., Wolff R., Yonehara S., Hannun Y. A., Seldin M. F. Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. Procedings of the National Academy of Science of the USA 1995; 92: 8443–8447
   PubMed Web of Science ®Google Scholar
• Wang J., Zheng L., Lobito A., Chan F., Dale J., Sneller M., Yao X., Puck J., Straus S., Lenardo M. Inherited human caspase-10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999; 98: 47–58
   PubMed Web of Science ®Google Scholar
• Vidal S., Kono D. H., Theofilopoulos A. N. Loci predisposing to autoimmunity in MRL-Faslpr and C57BL/6-Faslpr mice. Journal of Clinical Investigation 1998; 101: 696–702
   PubMed Web of Science ®Google Scholar
• Van Parijs L., Refaeli Y., Abbas A. K., Baltimore D. Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity 1999; 11: 763–770
   PubMed Web of Science ®Google Scholar
• Irmler M., Thome M., Hahne M., Schneider P., Hofinannn K. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195
   PubMed Web of Science ®Google Scholar
• Fuss I. J., Strober W., Dale J. K., Fritz S., Pearlstein G. R., Puck J. M. Characteristic T helper 2 cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by detective apoptosis and humoral autoimmunity. Journal of immunology 1997; 158: 1912–1918
   PubMed Web of Science ®Google Scholar
• Varfolomeev E. E., Boldin M. P., Goncharov T. M., Wallach D. A potential mechanism of “cross-talk” between the p55 tumor necrosis factor receptor and Fas/APO1: proteins binding to the death domains of the two receptors also bind to each other. Journal of Experimental Medicine 1996; 183: 1271–1275
   PubMed Web of Science ®Google Scholar
• Körner H., Cretney E., Wilhelm P., Kelly J., Rollinghoff M., Sedgwick J., Smyth M. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. Journal of Experimental Medicine 2000; 191: 89–96
   PubMed Web of Science ®Google Scholar
• Jenkins J. M., Keir M., McCune J. M. A membrane-bound Fas decoy receptor expressed by human thymocytes. Journal of Biological Chemistry, 275: 7988–7993
   PubMed Web of Science ®Google Scholar
• Knipping E., Krammer P. H., Onel K. B., Lehman T. J., Mysler E., Elkon K. B. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis and Rheumatology 1995; 38: 1935–1737
   Web of Science ®Google Scholar
• Goel N., Ulrich D. T., St. Clair E. W., Fleming J. A., Lynch D. H., Seldin M. F. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis and Rheumatology 1995; 38: 1938–1743
   Web of Science ®Google Scholar
• Wong B., Arron J., Choi Y. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. Journal of Experimental Medicine 1997; 186: 1939–1944
   PubMed Web of Science ®Google Scholar
• Combadiere B., Sousa C. R., Germain R. N., Lenardo M. J. Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands. Journal of Experimental Medicine 1998; 187: 349–355
   PubMed Web of Science ®Google Scholar
• Kroemer G., Zamzani N., Susin S. Mitochondrial control of apoptosis. Immunology Today 1997; 18: 44–51
   PubMedGoogle Scholar
• Yang E., Korsmeyer S. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88: 386–401
   PubMed Web of Science ®Google Scholar
• Armstrong R. C., Aja T., Xiang J., Gaur S., Krebs J. F., Hoang K., Bai X., Korsmeyer S. J., Karanewsky D. S., Fritz L. C., Tomaselli K. J. Fas-induced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors. Journal of Biological Chemistry 1996; 271: 16850–16855
   PubMed Web of Science ®Google Scholar
• Boise L., Thompson S. Bcl-XI can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Procedings of the National Academy of Science of the USA 1997; 94: 3759–3764
   PubMed Web of Science ®Google Scholar
• Warrier S., Kaplan J., Ravindranath Y. Persistent immune activation in children with Evans syndrome: evidence for a role of fas system. ASH 1998, Miami, Abstract number 711
   Google Scholar
• Vaishnaw A. K., Toubi E., Ohsako S., Drappa J., Buys S., Estrada J., Sitarz A., Zemel L., Chu J. L., Elkon K. B. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. The Journal of Arthritis and reumatology 1999; 42: 1833–1842
   PubMed Web of Science ®Google Scholar
• Mysler E., Bin P., Drappa J., Ramos P., Friedman S. M., Krammer P. H., Elkon K. B. The apoptosis-1/Fas protein in human systemic lupus erythematosus. Journal of clinical Investigation 1994; 93: 1029–1034
   PubMed Web of Science ®Google Scholar
• Debatin K. M., Krammer P. H. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. Leukemia 1995; 9: 815–820
   PubMed Web of Science ®Google Scholar
• van der Werff ten Bosch J. E., Demanet C., Balduck N., Bakkus M. H. C., De Raeve H., Desprechins B., Otten J., Thielemans K. The use of the anti malaria drug Fansidar (pyrimethamine and sulfadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency. British Journal of Heamatology 1998; 102: 578–581
   PubMed Web of Science ®Google Scholar